As More Leading Doctors Oppose Avandia, Will Indian Regulators Propose A Ban?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Leading Indian doctors have begun speaking out against GlaxoSmithKline's anti-diabetes brand Avandia (rosiglitazone) - branded as Windia in the Indian market - after U.S.FDA restricted the drug's use and European regulatory authorities ordered a complete withdrawal of the medicine from the market